Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Summit Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY NOTED THAT OUR PARTNER, AKESO, INC. (AKESO, HKEX CODE: 9926.HK) PUBLISHED RESULTS FROM THE PHASE III HARMONI-A TRIAL, CONDUCTED IN CHINA AND SPONSORED BY AKESO, FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB. THE DATA WAS PRESENTED TODAY AS PART OF THE ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC 2025) IN NATIONAL HARBOR, M.

IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES A STATISTICALLY SIGNIFICANT BENEFIT IN OVERALL SURVIVAL WITH A HAZARD RATIO OF 0.74 IN 2L+ TREATMENT OF PATIENTS WITH EGFRM NSCLC IN HARMONI-A STUDY CONDUCTED BY AKESO IN CHINA

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN AND PRESENT AT FOUR UPCOMING INVESTOR CONFERENCES DURING THE REMAINDER OF THIS YEAR. MEMBERS OF THE SUMMIT LEADERSHIP TEAM WILL PARTICIPATE IN FIRESIDE CHATS AND INDIVIDUAL INVESTOR MEETINGS AT THE FOLLOWING CONFERENCES: UBS GLOBAL HEALTHCARE CONFERENCE IN PALM BEACH ON MONDAY, NOVEMBER 10, 2025 AT 3:30PM EST JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LON.

SUMMIT THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY ANNOUNCED THAT RESULTS FROM THE PHASE III HARMONI-A TRIAL, CONDUCTED IN CHINA AND SPONSORED BY OUR PARTNER, AKESO, INC. (AKESO, HKEX CODE: 9926.HK), FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB, WILL BE PRESENTED AS PART OF THE ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC 2025) IN NATIONAL HARBOR, MARYLAND (WASHINGTON D.C.

OVERALL SURVIVAL DATA FROM HARMONI-A, FEATURING IVONESCIMAB IN COMBINATION WITH CHEMOTHERAPY VS. CHEMOTHERAPY IN 2L+ TREATMENT OF PATIENTS WITH EGFRM NSCLC IN CHINA, TO BE SHOWCASED AT SITC 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY ANNOUNCED THAT THE COMPANY HAS ACCEPTED OFFERS FROM MULTIPLE LEADING BIOTECH INSTITUTIONAL AND INDIVIDUAL INVESTORS TO PURCHASE AN AGGREGATE OF APPROXIMATELY 26.68 MILLION SHARES OF THE COMPANY'S COMMON STOCK AT $18.74 PER SHARE, THE CLOSING PRICE ON TUESDAY, OCTOBER 21, 2025, FOR AGGREGATE GROSS AND NET PROCEEDS TO THE COMPANY OF APPROXIMATELY $500 MILLION. ROBERT W. DUGGAN, THE COMPANY'S C.

SUMMIT THERAPEUTICS RAISES $500 MILLION IN PRIVATE PLACEMENT

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) ("SUMMIT," "WE," OR THE "COMPANY") TODAY REPORTS ITS FINANCIAL RESULTS AND PROVIDES AN UPDATE ON OPERATIONAL PROGRESS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. PLANNED BLA SUBMISSION FOR IVONESCIMAB IN Q4 2025 TODAY, SUMMIT ANNOUNCES THAT, BASED ON THE RESULTS OF THE HARMONI CLINICAL TRIAL, IT PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) IN ORDER TO SEEK APPROVAL FOR IVONESCIMAB PLUS CHEMOTHERAPY FOR THIS PROPOSED IN.

SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) ("SUMMIT," "WE," OR THE "COMPANY") TODAY ANNOUNCED RESULTS FROM THE PHASE III HARMONI-6 TRIAL, CONDUCTED IN CHINA AND SPONSORED BY OUR PARTNER, AKESO, INC. (HKEX CODE: 9926.HK), FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB. THE DATA WAS PRESENTED TODAY AS PART OF THE PRESIDENTIAL SYMPOSIUM AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2025 CONGRESS (ESMO 2025) IN BERLIN, GERMANY. THE.

IVONESCIMAB WITH CHEMOTHERAPY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 40% COMPARED TO TISLELIZUMAB (PD-1 INHIBITOR) PLUS CHEMOTHERAPY IN 1L TREATMENT OF PATIENTS WITH SQUAMOUS NSCLC IN THE HARMONI-6 STUDY CONDUCTED BY AKESO IN CHINA

NEW YORK , OCT. 18, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. - SMMT

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) ("SUMMIT," "WE," OR THE "COMPANY") TODAY ANNOUNCED THE EXPANSION OF ITS PHASE III CLINICAL DEVELOPMENT PROGRAM OF THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB, INTO COLORECTAL CANCER (CRC) WITH THE INITIATION OF THE GLOBAL PHASE III HARMONI-GI3 TRIAL. SUMMIT IS STARTING A PHASE III CLINICAL STUDY, HARMONI-GI3, TO EVALUATE IVONESCIMAB PLUS CHEMOTHERAPY COMPARED TO BEVACIZUMAB PLUS CHEMOTHERAPY.

SUMMIT THERAPEUTICS ANNOUNCES EXPANSION OF IVONESCIMAB GLOBAL PHASE III DEVELOPMENT PROGRAM WITH HARMONI-GI3 STUDY IN 1L COLORECTAL CANCER

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) WILL HOST AN ESMO DATA UPDATE AND THIRD QUARTER EARNINGS CALL ON MONDAY, OCTOBER 20, 2025, BEFORE THE MARKET OPENS. THE ESMO DATA RELATES TO THE PLANNED DISCLOSURE OF THE HARMONI-6 CLINICAL TRIAL DATA. AS A REMINDER, THE PHASE III HARMONI-6 TRIAL, CONDUCTED IN CHINA AND SPONSORED BY OUR PARTNER, AKESO, INC. (HKEX CODE: 9926.HK), FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECI.

SUMMIT THERAPEUTICS TO HOST ESMO DATA UPDATE & THIRD QUARTER EARNINGS CALL ON OCTOBER 20, 2025

NEW YORK , OCT. 13, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 8, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 3, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , SEPT. 28, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT).

NEW YORK, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. (SUMMIT OR THE COMPANY) (NASDAQ: SMMT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. - SMMT

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY ANNOUNCED THE GRANT OF INDUCEMENT AWARDS OF OPTIONS TO PURCHASE A COLLECTIVE TOTAL OF UP TO 65,750 SHARES OF COMMON STOCK. AWARDS WERE MADE TO EIGHT NEW EMPLOYEES OF THE COMPANY. THE AWARDS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES BECOMING EMPLOYEES OF THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND HAVE BEEN APPROVED BY THE COMPANY'S COMPENSATION COMMITT.

SUMMIT THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) ("SUMMIT," "WE," OR THE "COMPANY") TODAY ANNOUNCED THAT DATA FROM THE PHASE III HARMONI-6 TRIAL, CONDUCTED IN CHINA AND SPONSORED BY OUR PARTNER, AKESO, INC. (HKEX CODE: 9926.HK), FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB, WILL BE FEATURED AS PART OF THE PRESIDENTIAL SYMPOSIUM AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2025 CONGRESS (ESMO 2025) WHICH TAKES PLACE FROM OCTOBER 17.

HARMONI-6, FEATURING IVONESCIMAB COMBINED WITH CHEMOTHERAPY VS. TISLELIZUMAB PLUS CHEMOTHERAPY IN 1L TREATMENT OF PATIENTS WITH SQUAMOUS NSCLC IN CHINA, TO BE SHOWCASED IN PRESIDENTIAL SYMPOSIUM AT ESMO 2025

NEW YORK , SEPT. 23, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT).

NEW YORK , SEPT. 18, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT).

LOS ANGELES, SEPT. 16, 2025 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES SUMMIT THERAPEUTICS INC. INVESTORS ("SUMMIT" OR THE "COMPANY") (NASDAQ: SMMT) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

SUMMIT THERAPEUTICS INC. INVESTIGATED BY THE PORTNOY LAW FIRM

NEW YORK, SEPT. 10, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SUMMIT THERAPEUTICS INC. (SUMMIT OR THE COMPANY) (NASDAQ: SMMT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

LOS ANGELES, SEPT. 10, 2025 (GLOBE NEWSWIRE) -- THE ORIGINAL PRESS RELEASE, DISTRIBUTED TUESDAY, SEPTEMBER 9, 2025, INCORRECTLY STATED THAT A LAWSUIT WAS FILED AGAINST SUMMIT THERAPEUTICS, IN THE HEADLINE AND BODY OF THE RELEASE. THE PORTNOY LAW FIRM HAS COMMENCED AN INVESTIGATION INTO SUMMIT THERAPEUTICS INC. CONCERNING ALLEGED SECURITIES FRAUD. THE CORRECTED RELEASE FOLLOWS.

CORRECTION -- SUMMIT THERAPEUTICS INC. INVESTIGATED BY THE PORTNOY LAW FIRM

INVESTORS CAN CONTACT THE LAW FIRM AT NO COST TO LEARN MORE ABOUT RECOVERING THEIR LOSSES

SUMMIT THERAPEUTICS INC. INVESTORS: PLEASE CONTACT THE PORTNOY LAW FIRM TO RECOVER YOUR LOSSES. SEPTEMBER 24, 2025 DEADLINE TO FILE LEAD PLAINTIFF MOTION.

THE OVERALL SURVIVAL (OS) HAZARD RATIO (HR) IN THE HARMONI TRIAL WAS 0.78, WITH A NOMINAL P-VALUE OF 0.0332 IN THE NORTH AMERICAN PATIENTS, THE OS HR WAS 0.70 THE HARMONI TRIAL HAS ALREADY DEMONSTRATED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT PROGRESSION-FREE SURVIVAL (PFS) OUTCOMES IN THE HARMONI TRIAL, CLINICAL ENDPOINT BENEFITS, INCLUDING OS AND PFS, WERE CONSISTENT ACROSS WESTERN AND ASIAN PATIENT POPULATIONS, AND THESE RESULTS WERE ALSO IN ALIGNMENT WITH THE CLINICAL DATA FROM THE HARMONI-A TRIAL CONDUCTED IN CHINA HONG KONG , SEPT. 7, 2025 /PRNEWSWIRE/ -- AKESO, INC. (HKEX: 9926.HK) IS PLEASED TO SHARE TODAY THAT ITS GLOBAL PARTNER, SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT), ANNOUNCED THE UPDATED OVERALL SURVIVAL (OS) RESULTS FROM THE GLOBAL PHASE III HARMONI CLINICAL TRIAL OF IVONESCIMAB, A NOVEL PD-1/VEGF BISPECIFIC ANTIBODY, AT THE PRESIDENTIAL SYMPOSIUM IN THE 2025 WORLD CONFERENCE ON LUNG CANCER (WCLC).

IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES CONSISTENT GLOBAL BENEFIT: HARMONI DATA UPDATE SHOWS OS HR=0.78, NOMINAL P=0.0332

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) ("SUMMIT," "WE," OR THE "COMPANY") TODAY ANNOUNCED DATA FROM THE PHASE III HARMONI TRIAL FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB. THE DATA WAS PRESENTED THIS MORNING AS PART OF THE PRESIDENTIAL SYMPOSIUM AT THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER'S (IASLC) 2025 WORLD CONFERENCE ON LUNG CANCER (WCLC 2025) IN BARCELONA, SPAIN. THE HARMONI PRESENTATION, IVONESCI.

LONGER-TERM FOLLOW-UP OF WESTERN PATIENTS SHOWED IMPROVING, FAVORABLE TREND IN OVERALL SURVIVAL IN GLOBAL PHASE III HARMONI CLINICAL TRIAL FOR IVONESCIMAB PLUS CHEMOTHERAPY IN 2L+ EGFRM NSCLC

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) WILL HOST A CALL TO DISCUSS THE IVONESCIMAB DATA FROM OUR GLOBAL PHASE III CLINICAL TRIAL, HARMONI, PRESENTED AS PART OF THE PRESIDENTIAL SYMPOSIUM AT THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER'S (IASLC) 2025 WORLD CONFERENCE ON LUNG CANCER (WCLC 2025) IN BARCELONA, SPAIN. THE CALL WILL BE HELD ON MONDAY, SEPTEMBER 8, 2025, AT 8:00AM ET AND WILL BE ACCESSIBLE THROUGH OUR WEBSITE, W.

Summit Therapeutics Inc.

SMMT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Summit Therapeutics Inc.

SMMT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SMMT